Shares of Biocon Ltd were trading in the green and 1% higher on 3 July after the company announced securing marketing approval in Europe for its two products. 

In its regulatory filing, the company announced securing marketing approval for its two biosimilars of Denosumab, which are Evfraxy and Venzuo. 

The company stated in an exchange filing that it has authorised Vevzuo for preventing bone complications in adults with advanced cancers involving bone, and for treating adults and skeletally mature adolescents with giant cell tumour of bone.

It also authorised Evfraxy for treating osteoporosis in men with prostate cancer at increased fracture risk, and for addressing bone loss associated with long-term systemic glucocorticoid therapy in adults.

“Clinical data show that both Denosumab biosimilars match the reference product in quality, safety, and efficacy,” the company added.

Biocon noted that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on April 25, 2025, leading to this marketing authorisation.

Shreehas Tambe, CEO and Managing Director of Biocon Biologics, said, “In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion, and support for healthcare systems in the region.”

At 11:55 am, the shares of Biocon were trading 0.54% higher at Rs 370.55 on NSE.

The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!